WHITEFISH, MT / June 10, 2014 / The U.S. cannabis industry grew 64% in 2013 and is expected to reach $2.34 billion by the end of 2014, according to ArcView Market Research
At the same time, the U.S. nutraceutical industry is projected to grow
at a 5% CAGR to reach $75.9 billion by 2018, according to RNCOS
. Cannabis Therapy (CTCO 0.96 1.05%)
is executing its product development strategy to benefit from both of
these trends, bringing biomedical methods and processes, as well as a
seasoned management team, to the cannabis space.
In an exclusive interview, the company’s President and CEO Soren
Mogelsvang sat down with CannabisFN’s Mike Elliott to discuss the
company’s distinctive business model and how it plans to capitalize on
the rapidly growing industries.
CannabisFN Executive Interview | Cannabis Therapy (CTCO) from TDM Financial on Vimeo.
Qualified to Lead
Cannabis Therapy’s skilled team consists of entrepreneurs and
business veterans with experience across both the nutraceutical and
biomedical industries. President and CEO Soren Mogelsvang is a biotech
executive with over 15 years of experience in translational research,
antibody development, and ISO compliant manufacturing with proven
development and operational skills.
On the Board of Directors, Guy Yachin, Cohava Gelber, and Vered
Caplan bring an accomplished track record from the biomedical industry.
Mr. Yachin is a serial biotech entrepreneur with a highly successful
track record; Dr. Gelber is a PhD with over 25 years of work in
developing immune-based therapeutics and diagnostics targeting cancer.
Ms. Caplan brings to the table a diverse background in the biotech
industry, having worked at several companies over the course of her
The team’s extensive background within the biotechnology and
pharmaceutical industries could prove invaluable in guiding the company
through the challenging early-stage cannabis industry. While pursuing a
strategy with minimal regulatory hurdles, the team’s experience should
ensure that its products are supported by science as well as being safe
and efficacious for consumers.
Cannabis Therapy differs from many other publicly traded medical
cannabis companies, such as GW Pharmaceuticals plc (NASDAQ: GWPH) or
Cannabis Science Inc. (OTC: CBIS), in that it’s focus is to target the
nutraceutical industry. By taking this approach, management aims to
minimize many of the regulatory hurdles associated with pushing a
pharmaceutical drug through the FDA approval process.
The company aims to identify existing hemp-based cannabis strains and
develop new proprietary cultivars with elevated cannabinoid content and
little or no THC. With an ISO-compliant cannabinoid extraction and
characterization process, the firm will adhere to strict biotechnology
and pharmaceutical standards in its development and manufacturing of new
products for the nutraceutical market.
In addition to developing nutraceuticals, management indicated that
it may also offer laboratory purification and testing services, along
with third party product development, to a select group of industry
partners in the future. The combination of developing proprietary
products and potentially joint venturing to develop additional products
could create a comprehensive portfolio with less risk.
The hemp plant contains over 450 different substances and is
practically devoid of the psychoactive THC (which creates the “high”
feeling associated with marijuana). Researchers have been drawn to the
human cannabinoid receptors and their potential to modulate the immune
system, and positively influence human health.
Cannabis Therapy plans to focus its initial efforts on developing
products for inflammatory diseases, where hemp has already been shown to
have medicinal potential. Future products could target indications such
as nausea, loss of appetite, insulin resistance, sleep disorders,
anxiety, and chronic pain, leveraging the vast medicinal potential of
the cannabis plant.
Cannabis Therapy has assembled a talented team and formulated a
unique strategy to capitalize on the growing cannabis and nutraceutical
industries. Since hemp is widely available and legal to grow in many
states (due to its low THC content) the company’s products will likely
face little regulatory scrutiny, while scientific studies have suggested
that its products could be highly efficacious.
Investors may want to take a closer look at the company as an
alternative to companies like Vape Holdings Inc. (OTC: VAPE) or Hemp
Inc. (OTC: HEMP).
To Sign Up For Future Email Updates:
For more information, see the following resources:
- Company Website
- OTC Markets Profile
Disclaimer: Except for the historical information presented herein,
matters discussed in this release contain forward-looking statements
that are subject to certain risks and uncertainties that could cause
actual results to differ materially from any future results, performance
or achievements expressed or implied by such statements. Emerging
Growth LLC is not registered with any financial or securities regulatory
authority, and does not provide nor claims to provide investment advice
or recommendations to readers of this release. For making specific
investment decisions, readers should seek their own advice. Emerging
Growth LLC may be compensated for its services in the form of cash-based
compensation or equity securities in the companies it writes about, or a
combination of the two. For full disclosure please visit: http://secfilings.com/Disclaimer.aspx
SOURCE: Emerging Growth LLC